Pseudoephedrine "massive diversion" has been cited by DEA, NDMA says.
This article was originally published in The Tan Sheet
Executive Summary
PSEUDOEPHEDRINE "MASSIVE DIVERSION" CITED BY DEA, the Nonprescription Drug Manufacturers Association informed FDA in Sept. 27 comments. NDMA told the agency that it learned of the widespread diversion of pseudoephedrine for use in illegal drug synthesis in a recent meeting with the Drug Enforcement Administration. DEA has attributed the diversion in part to increasing state and federal restrictions on ephedrine availability and said it intends to take steps to counter the problem, NDMA noted.